Full Breakdown
Replimune's RP1 Receives FDA Resubmission Acceptance for Advanced Melanoma Treatment
10/20/2025, 8:28:36 PM
FDA Acceptance Marks a Turning Point for Replimune
Replimune Group Inc. experienced a significant surge in its stock price following the U.S. Food and Drug Administration's (FDA) acceptance of its resubmitted Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec), an oncolytic immunotherapy designed to treat advanced melanoma. The FDA has set a target review date of April 10, 2026, under a Class II resubmission timeline. This decision comes after the FDA had previously issued a complete response letter (CRL) in July 2025, citing concerns regarding the trial design and patient population.
Background on RP1 and Regulatory Challenges
RP1 is intended for patients with advanced melanoma who have progressed on anti-PD-1 therapies, specifically in combination with Bristol Myers Squibb's nivolumab (Opdivo). The therapy utilizes a genetically modified strain of the herpes simplex virus to induce tumor cell death and stimulate an immune response. Following the FDA's initial rejection, Replimune undertook extensive efforts to address the agency's concerns, incorporating additional data and analyses into the resubmission.
Stock Market Reaction and Investor Sentiment
Following the FDA's announcement, Replimune's stock price soared by approximately 108%, recovering from a year-to-date decline of 63%. Analysts have noted that this development is a positive signal for the biotech sector, which has been apprehensive due to recent drug denials. BMO Capital Markets analyst Evan Seigerman remarked that the acceptance of the resubmission is a "clear win for the company and the biotech space more broadly."
Official Statements and Company Insights
Replimune's CEO, Sushil Patel, expressed satisfaction with the FDA's acceptance, emphasizing the strong risk-benefit profile of RP1 combined with nivolumab for patients with limited treatment options. He stated, “We are pleased the agency has accepted the resubmission of our BLA for RP1. RP1 plus nivolumab offers a strong risk benefit profile where there are few options for patients with advanced melanoma.”
Criticism and Opposition
Despite the positive news, skepticism remains regarding the FDA's evolving stance on drug approvals. Some analysts caution that the agency's recent leadership changes and its tougher approach to single-arm trials may still pose challenges for Replimune. Vinay Prasad, a former FDA official, had previously criticized the approval of drugs based on limited trial data, highlighting the ongoing debate within the regulatory landscape.
Conflicting Reports and Gaps
While the FDA's acceptance is a significant milestone, the initial rejection raised questions about the adequacy of the Phase III IGNYTE trial. Discrepancies exist regarding the trial's effectiveness and the diversity of its patient population, which were central to the FDA's concerns. An open letter from 22 scientists involved in the trial urged the FDA to reconsider its decision, indicating ongoing contention around the drug's approval process.
What's Next for Replimune
With the FDA's acceptance of the resubmission, Replimune is positioned to continue its pursuit of regulatory approval for RP1. The company plans to work closely with the FDA throughout the review period, aiming for a favorable outcome that could expand treatment options for patients battling advanced melanoma. The upcoming months will be critical as the company navigates the regulatory landscape leading up to the April 2026 decision.
